Stockscreener 앱 받기
560.01
0.95%
-5.39
시장 영업 전:
560.00
-0.010
-0.00%
전일 마감가:
$565.40
열려 있는:
$564.87
하루 거래량:
379.02K
Relative Volume:
1.16
시가총액:
$12.91B
수익:
$1.13B
순이익/손실:
$-309.44M
주가수익비율:
-43.75
EPS:
-12.8001
순현금흐름:
$-275.41M
1주 성능:
+6.04%
1개월 성능:
+17.43%
6개월 성능:
+8.94%
1년 성능:
+81.47%
1일 변동 폭
$548.36
$569.44
1주일 범위
$522.06
$569.44
52주 변동 폭
$286.44
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
560.01 | 12.91B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
496.50 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.95 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.49 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.79 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.13 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Insider Monkey
Trading the Move, Not the Narrative: (MDGL) Edition - Stock Traders Daily
5 Best Under-the-Radar Stocks to Invest In - Insider Monkey
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal gives seven new employees stock awards to join the company - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Navigating a Promising 28.52% Upside Potential - DirectorsTalk Interviews
MDGLMadrigal Pharmaceuticals Inc Latest SEC Filings - Finviz
Ribocure and Madrigal nominate siRNA drug candidate for MASH - BioWorld News
Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Lelezard
Madrigal and Ribo start IND-enabling studies after MASH milestone - Stock Titan
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating - Investing.com
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $900 - Moomoo
Price to earnings forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Madrigal Pharmaceuticals, Inc.(NasdaqGS:MDGL) added to Russell 1000 Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
Enterprise value to EBIT forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Madrigal Pharmaceuticals, Inc.(NasdaqGS: MDGL) added to Russell 1000 Index - marketscreener.com
Price to sales forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
Enterprise value to EBIT forward of Madrigal Pharmaceuticals, Inc. – SWB:YDO1 - TradingView
(MDGL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MDGL) - TradingView
MDGL Forecast — Price Target — Prediction for 2027 - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating at $900 By Investing.com - Investing.com Canada
MDGL PE Ratio & Valuation, Is MDGL Overvalued - Intellectia AI
Madrigal Pharmaceuticals stock holds at $511.61 as SOLAR Conference event nears, Madrigal Pharmaceuticals - Traders Union
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A Biotech Gem with a 34% Upside Potential - DirectorsTalk Interviews
Madrigal Pharmaceuticals Stockweekly review and NASH sector context - AD HOC NEWS
Madrigal Pharmaceuticals Inc - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Madrigal Shareholders Approve 2026 Equity Compensation Plans - The Globe and Mail
[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Madrigal (MDGL) director Richard Levy receives new RSU and stock option grants - Stock Titan
Madrigal Pharmaceuticals (MDGL) director granted RSUs and stock options - Stock Titan
Madrigal (MDGL) director James Daly granted RSUs and 766-share option - Stock Titan
Madrigal (MDGL) director receives stock grants and 681-share option award - Stock Titan
Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards - Stock Titan
Madrigal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LPmoomoo - Moomoo
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals shareholders approve new equity plans and board changes - Investing.com Nigeria
Madrigal (NASDAQ: MDGL) updates equity, ESPP and deferred pay plans - Stock Titan
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Madrigal Cooperating With NICE On MASH Drug After Provisional English Funding Rejection - Citeline News & Insights
Price-Driven Insight from (MDGL) for Rule-Based Strategy - Stock Traders Daily
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Globe and Mail
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.48%
0.70%
자본화:
|
볼륨(24시간):